The Asia-Pacific chronic idiopathic constipation drug market was valued to be at $xx million in the year 2017. The market is poised to rise with the highest CAGR of 10.12% during the forecast period of 2018-2026. The key factor due to which the APAC CIC drug market is growing is the rising medical tourism. Patients from all over the globe travel to APAC countries to undergo various surgeries and procedural treatments.

ASIA PACIFIC CHRONIC IDIOPATHIC CONSTIPATION DRUG MARKET FORECAST 2018-2026

Asia Pacific Chronic Idiopathic Constipation Drug Market by Drug Type (Lubiprostone, Linaclotide & Others) by Prescription (Prescribed Drugs, Over the Counter Drugs) by Geography

Request free sample

Report Summary

Changing dietary habits, rising elderly population, cancer or other systematic diseases that can lead to CIC, along with improved and efficient drugs in the pipeline, and the increasing constipation problems due to side effects of prescribed medication are some of the factors which are driving the market growth. The countries analyzed for this region include China, Japan, and the rest of Asia-Pacific. The India CIC drug market is forecasted to rise with the fastest CAGR. Favourable regulations enable the country to explore more in advance technologies and medical innovations. Also, local drugs manufacturers from China are giving a tough competition to some global brands as they capture small local markets with low costing and better alternatives.

Progenics Pharmaceuticals Inc, Ferring International Center S.A, Theravance Biopharma Inc, Chugai Pharmaceutical, Allergens, Cosmo Pharmaceuticals SA, Synergy Pharmaceuticals, Valeant Pharmaceuticals International, GlaxoSmithKline, Daiichi Sankyo Co Ltd, Pfizer, Ironwood Pharmaceuticals Inc, Roche Holding Ag, Salix Pharmaceuticals Ltd, Merck Sharp & Dohme, Sucampo Pharmaceuticals Inc, Bayer Ag, and Eli Lilly And Company are some of the noted companies in the market.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
RESEARCH METHODOLOGY
- SOURCES OF DATA
  - SECONDARY DATA
  - PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
  - LINACLOTIDE MARKET TO WITNESS THE FASTEST GROWTH RATE DURING THE FORECAST PERIOD
  - OVER THE COUNTER SEGMENT TO HOLD MAJOR SHARE OF THE CIC DRUG MARKET BY PRESCRIPTION TYPE

MARKET OVERVIEW
- MARKET DEFINITION
- KEY MARKET INSIGHTS
- ATTRACTIVE INVESTMENT SCENARIO
- POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
- MARKET DRIVERS
  - MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
  - CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
  - INCREASING ELDERLY POPULATION
  - IMPROVED AND EFFICIENT DRUGS IN PIPELINE
  - INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
- RESTRAINTS
  - SURGICAL TREATMENTS
  - UNAWARENESS AND IGNORANCE AMONG PEOPLE
- OPPORTUNITIES
  - INCREASING DEMAND FOR CIC DRUG FROM THE APAC MARKET
  - HIGH UNMET NEEDS
- CHALLENGES
  - SIDE EFFECTS OF CIC DRUGS

ASIA PACIFIC CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 ($ MILLION)
- OVERVIEW
  - LUBIPROSTONE
  - LINACLOTIDE
  - OTHERS
- PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
- PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
- PRESCRIBED DRUGS
- OVER THE COUNTER DRUGS
KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
  - INTENSITY OF COMPETITIVE RIVALRY
  - BARGAINING POWER OF SUPPLIERS
  - BARGAINING POWER OF BUYERS
  - THREAT OF SUBSTITUTE PRODUCTS
  - THREAT OF NEW ENTRANTS
- REGULATORY FRAMEWORK
- VENDOR LANDSCAPE
- OPPORTUNITY MATRIX
ASIA PACIFIC CIC DRUGS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- AUSTRALIA
- REST OF ASIA PACIFIC
COMPANY PROFILES
- ALLERGENS
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- CHUGAI PHARMACEUTICAL
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- FERRING INTERNATIONAL CENTER S.A.
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - SCOT ANALYSIS
- SYNERGY PHARMACEUTICALS
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - SCOT ANALYSIS
- PFIZER
  - OVERVIEW
  - PFIZER PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- GLAXOSMITHKLINE
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- ROCHE HOLDING AG
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- SANOFI
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - SCOT ANALYSIS
- BAYER AG
  - OVERVIEW
  - PRODUCTS PORTFOLIO
  - SCOT ANALYSIS
- MERCK SHARP & DOHME
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- ELI LILLY AND COMPANY
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- SALIX PHARMACEUTICALS LTD
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- SUCAMPO PHARMACEUTICALS INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- IRONWOOD PHARMACEUTICALS INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- VALEANT PHARMACEUTICALS INTERNATIONAL
  - OVERVIEW
- DAIICHI SANKYO CO LTD
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- COSMO PHARMACEUTICALS SA
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- PROGENICS PHARMACEUTICALS INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- THERAVANCE BIOPHARMA INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS

TABLE LIST

TABLE 1 ASIA PACIFIC CIC DRUG MARKET BY COUNTRIES 2018-2026 ($ MILLION)

TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION

TABLE 3 CONSTIPATION IN PARKINSON’S DISEASE

TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION

TABLE 5 ASIA PACIFIC CIC DRUGS MARKET BY DRUG TYPE 2018-2026 ($ MILLION)

TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 7 PRODUCT PROFILE (LINACLOTIDE)

TABLE 8 PRODUCT PROFILE (BISACODYL)

TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)

TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)

TABLE 11 ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)

TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS

TABLE 13 ASIA PACIFIC CIC DRUGS MARKET BY COUNTRY 2018-2026 ($ MILLION)

TABLE 14 CHINA CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)

TABLE 15 CHINA CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)

TABLE 16 JAPAN CIC DRUG MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)

TABLE 17 JAPAN CIC DRUG MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)

FIGURE LIST

FIGURE 1 ASIA PACIFIC CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 2 ASIA PACIFIC CIC DRUG MARKET BY DRUG TYPE 2018-2026 ($ MILLION)

FIGURE 3 ASIA PACIFIC CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2017 ($ MILLION)

FIGURE 4 CAUSES OF CONSTIPATION

FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014

FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE

FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS

FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION

FIGURE 9 NEED OF SURGERY PROCESS

FIGURE 10 APAC CIC MARKET 2018-2026 ($ MILLION)

FIGURE 11 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM

FIGURE 12 ASIA PACIFIC LUBIPROSTONE DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 13 ASIA PACIFIC LINACLOTIDE DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 14 ASIA PACIFIC OTHER DRUGS MARKET 2018-2026 ($ MILLION)

FIGURE 15 ASIA PACIFIC PRESCRIBED CIC DRUGS MARKET 2018-2026 ($ MILLION)

FIGURE 16 ASIA PACIFIC OVER THE COUNTER CIC DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 17 ASIA PACIFIC CIC DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 18 CHINA CIC DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 19 JAPAN CIC DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 20 INDIA CIC DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 21 SOUTH KOREA CIC DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 22 AUSTRALIA CIC DRUG MARKET 2018-2026 ($ MILLION)

FIGURE 23 REST OF APAC CIC DRUG MARKET 2018-2026 ($ MILLION)

Segmentation

ASIA PACIFIC CIC DRUGS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- AUSTRALIA
- REST OF ASIA PACIFIC
ASIA PACIFIC CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 ($ MILLION)
- OVERVIEW
  - LUBIPROSTONE
  - LINACLOTIDE
  - OTHERS
- PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
- PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
ASIA PACIFIC CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
- PRESCRIBED DRUGS
- OVER THE COUNTER DRUGS